Bisphosphonates Related Ocular Side Effects: A Case Series and Review of Literature. (17th November 2022)

• Record Type: Journal Article
• Authors: Gendelman, Omer; Tripto - Shkolnik, Liana; Vered, Iris; Lidar, Merav
• Is Part Of: Ocular immunology and inflammation. Volume 30:Number 7/8(2022)
• Page Start: 1995
• Page End: 1999
• Publication Date: 2022-11-17
• Subjects: Bisphosphonates -- ocular inflammation -- γδ T cells -- IL-17; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2021.1922705
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Objective: To describe the clinical features of patients with bisphosphonate related ocular side effects (BROSE). Methods: The medical records of all patients with BROSE between January 2009 and December 2019 were reviewed. Results: Nine cases with BROSE were identified. All subjects were female. Median age at diagnosis was of 69 years. The leading indication for bisphosphonate treatment was osteoporosis (n=7), Paget's disease of bone (n=1) and breast cancer (n=1). Six (66.67%) patients presented with uveitis, one (11%) episcleritis and two (22%) with orbital inflammation. Five events (55.5%) occurred within 10 days of initiating the bisphosphonate and the rest (44.44%) developed within 2 weeks to 3 years later. Four (44.44%) patients had concurrent thyroid disease. An association was found between underlying thyroid disease or autoimmunity. Conclusion: BROSE is an uncommon complication of bisphosphonate therapy occurring more frequently in patients with an autoimmune predisposition.